Literature DB >> 17597479

Long-term administration of the low-dose risperidone in schizotaxia subjects.

Janusz K Rybakowski1, Wiktor Drozdz, Alina Borkowska.   

Abstract

The term schizotaxia is currently defined as a syndrome of neuropsychological deficits and negative symptoms found in relatives of schizophrenic patients. The aim of this study was to assess the effect of long-term treatment with the low-dose risperidone on cognitive and social functioning in seven schizotaxia patients. There were four males and three females, aged between 17 and 44 years, first-degree (four patients) or second-degree (three patients) relatives of schizophrenic patients. Schizotaxia was recognized in them on account of neuropsychological and social function impairment. They all consented to risperidone administration, 1-2 mg/day. Duration of risperidone treatment has ranged between 3-7 years. In all subjects, the continuous treatment with risperidone brought about a marked improvement in their cognitive, social, and vocational functioning. Neuropsychological testing after 6-24 months showed significant improvement on such tests as Wisconsin Card Sorting Test (WCST), Trail Making Test (TMT), and Stroop Test. Discontinuation of treatment after 3-4 years did not cause deterioration of functioning. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597479     DOI: 10.1002/hup.863

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  1 in total

1.  Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.

Authors:  William S Stone; Xiaolu Hsi; Anthony J Giuliano; Liwen Tan; Shaochun Zhu; Lingjiang Li; Larry J Seidman; Ming T Tsuang
Journal:  Asian J Psychiatr       Date:  2012-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.